Physiomics plc
("Physiomics" or the "Company")

Result of AGM

Issue of Equity, TVR, and Directors' Dealing

The Annual General Meeting of Physiomics was held today at 10.30 a.m. (GMT) at Strand Hanson, 26 Mount Row, Mayfair, London, W1K 3SQ. The Company is pleased to confirm that all resolutions put to shareholders were duly passed.

Full details of the poll results are set out below:

Resolution	For	Against	Discretion to Chairman	Withheld	Total
01	34,189,515	334,719	Nil	2,383	34,526,617
02	31,959,123	386,078	Nil	2,181,416	34,526,617
03	33,335,879	334,719	Nil	856,019	34,526,617
04	33,335,879	334,719	Nil	856,019	34,526,617
05	33,335,879	334,719	Nil	856,019	34,526,617
06	33,327,858	334,719	Nil	864,040	34,526,617
07	33,328,453	334,719	Nil	863,445	34,526,617
08	34,140,207	384,027	Nil	2,383	34,526,617
09	33,335,879	334,719	Nil	856,019	34,526,617
10	32,019,098	334,719	Nil	2,172,800	34,526,617

The number of shares in issue at 6:30 p.m. (UK) on 4 November 2026 was 453,208,718. The Company does not hold any shares in treasury.

Issue of Equity

As announced on 30 June 2026, the board of directors of Physiomics (the "Board" or the "Directors") agreed to receive new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in lieu of part of their cash remuneration. Following the AGM, Nick Tulloch, Chairman, will be issued 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will be issued 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board.

Admission and Total Voting Rights

Application has been made for 14,000,000 new Ordinary Shares to be admitted to trading on AIM ("Admission"). Admission is expected to occur on or around 8:00 a.m. on 11 November 2026. The new Ordinary Shares will rank *pari passu* in all respects with the existing Ordinary Shares.

Following Admission, the Company's enlarged share capital will comprise 467,208,718 Ordinary Shares of 1 pence each. Therefore, the total number of voting rights in the Company will be 467,208,718. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in the Company, or a change to their interest in the Company, under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

ENDS

For more information about Physiomics and its services, please visit www.physiomics.co.uk.

Enquiries:

Physiomics plc **Email: info@physiomics.co.uk**
Mike Whitlow

Strand Hanson Ltd (NOMAD and Broker) **Tel: +44 (0) 20 7409 3494**
James Dance & James Bellman

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

<table>
<tr><td>1.</td><td colspan="2">Details of the person discharging managerial responsibilities / person closely associated</td></tr>
<tr><td>a)</td><td>Name</td><td>PDMRs:<table><tr><td>Nick Tulloch</td><td>Non-Executive Chairman</td></tr><tr><td>Mike Whitlow</td><td>Executive Director</td></tr><tr><td>Ian Bagnall</td><td>Finance Director and Company Secretary</td></tr></table></td></tr>
<tr><td>2.</td><td colspan="2">Reason for the Notification</td></tr>
<tr><td>a)</td><td>Position/status</td><td>See 1a) above</td></tr>
<tr><td>b)</td><td>Initial notification/Amendment</td><td>Initial Notification</td></tr>
<tr><td>3.</td><td colspan="2">Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</td></tr>
<tr><td>a)</td><td>Name</td><td>Physiomics Plc</td></tr>
<tr><td>b)</td><td>LEI</td><td>213800A71DSZ6ABMTQ91</td></tr>
<tr><td>4.</td><td colspan="2">Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted</td></tr>
<tr><td rowspan="2">a)</td><td>Description of the Financial instrument, type of instrument</td><td>Ordinary Shares of 0.4p each in Physiomics Plc</td></tr>
<tr><td>Identification code</td><td>ISIN: GB00BDR6W943</td></tr>
<tr><td>b)</td><td>Nature of the transaction</td><td>Remuneration Shares</td></tr>
<tr><td>c)</td><td>Price(s) and volume(s)</td><td><table><tr><td>Name</td><td>Price(s)</td><td>Volume(s)</td></tr><tr><td>Nick Tulloch</td><td>£0.005</td><td>4,000,000</td></tr><tr><td>Mike Whitlow</td><td>£0.005</td><td>5,000,000</td></tr><tr><td>Ian Bagnall</td><td>£0.005</td><td>5,000,000</td></tr></table></td></tr>
<tr><td>d)</td><td>Aggregated information:</td><td></td></tr>
<tr><td></td><td>- Aggregated volume</td><td>14,000,000</td></tr>
<tr><td></td><td>- Price</td><td>£0.005</td></tr>
<tr><td>e)</td><td>Date of the transaction</td><td>5 November 2026</td></tr>
<tr><td>f)</td><td>Place of the transaction</td><td>Outside a trading venue</td></tr>
</table>